We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+29.88%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$171M
AUM Growth
+$38.4M
Cap. Flow
+$19.7M
Cap. Flow %
11.56%
Top 10 Hldgs %
54.57%
Holding
80
New
11
Increased
19
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
LRCX icon
Lam Research
LRCX
+$6.27M
2
NTLA icon
Intellia Therapeutics
NTLA
+$3.52M
3
CMPX icon
Compass Therapeutics
CMPX
+$3.32M
4
BCYC
Bicycle Therapeutics
BCYC
+$2.28M
5
SLDB icon
Solid Biosciences
SLDB
+$2.22M

Top Sells

Rank Stock Value
1
AXGN icon
Axogen
AXGN
+$2.12M
2
INBX icon
Inhibrx
INBX
+$1.91M
3
QURE icon
uniQure
QURE
+$1.85M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$1.16M
5
PRTA icon
Prothena Corp
PRTA
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.96%
2 Technology 19.61%
3 Energy 3.55%
4 Materials 0.54%
5 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLAC icon
1
KLA
KLAC
$278B
$26.6M 15.57%
218,830
– –
BMY icon
2
Bristol-Myers Squibb
BMY
$124B
$16.3M 9.56%
302,842
-14,000
-4% -$674K
CMPX icon
3
Compass Therapeutics
CMPX
$369M
$8.55M 5.01%
1,592,938
+720,000
+82% +$3.32M
STOK icon
4
Stoke Therapeutics
STOK
$1.81B
$8.25M 4.83%
260,000
+50,000
+24% +$1.5M
LRCX icon
5
Lam Research
LRCX
$392B
$6.9M 4.04%
+40,329
New +$6.27M
OLMA icon
6
Olema Pharmaceuticals
OLMA
$1B
$6.72M 3.94%
269,000
+95,000
+55% +$1.69M
GPCR icon
7
Structure Therapeutics
GPCR
$3.45B
$6.26M 3.66%
90,000
+12,000
+15% +$490K
PTGX icon
8
Protagonist Therapeutics
PTGX
$9.06B
$4.8M 2.81%
55,000
+7,000
+15% +$573K
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.38B
$4.57M 2.67%
171,000
– –
OVV icon
10
Ovintiv
OVV
$16.2B
$4.21M 2.47%
107,500
– –
PRTA icon
11
Prothena Corp
PRTA
$453M
$4.21M 2.47%
441,019
-108,000
-20% -$1.1M
SLDB icon
12
Solid Biosciences
SLDB
$858M
$3.98M 2.33%
705,955
+409,000
+138% +$2.22M
NBIX icon
13
Neurocrine Biosciences
NBIX
$17.2B
$3.86M 2.26%
27,190
-1,500
-5% -$217K
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$3.6M 2.11%
253,000
– –
BCYC
15
Bicycle Therapeutics
BCYC
$294M
$3.28M 1.92%
462,700
+308,700
+200% +$2.28M
PHAT icon
16
Phathom Pharmaceuticals
PHAT
$873M
$3.24M 1.89%
195,000
+110,000
+129% +$1.57M
CSTL icon
17
Castle Biosciences
CSTL
$733M
$3.14M 1.84%
80,600
-30,000
-27% -$967K
NTLA icon
18
Intellia Therapeutics
NTLA
$1.59B
$2.84M 1.66%
315,400
+255,400
+426% +$3.52M
IMNM icon
19
Immunome
IMNM
$2.53B
$2.79M 1.63%
130,000
+25,000
+24% +$439K
CORT icon
20
Corcept Therapeutics
CORT
$9.72B
$2.34M 1.37%
67,200
– –
VERA icon
21
Vera Therapeutics
VERA
$2.76B
$2.23M 1.3%
+44,000
New +$1.56M
QDEL icon
22
QuidelOrtho
QDEL
$1.19B
$2.07M 1.21%
72,548
– –
NVCR icon
23
NovoCure
NVCR
$1.84B
$1.97M 1.15%
152,100
+50,000
+49% +$642K
BDSX icon
24
Biodesix
BDSX
$209M
$1.95M 1.14%
286,804
– –
CYTK icon
25
Cytokinetics
CYTK
$10.9B
$1.91M 1.12%
30,000
– –
1
2 3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Birchview Capital held 80 positions worth $171M, up 29% from $132M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Birchview Capital deployed $19.7M of net new capital in Q4 2025, opening 11 new positions and adding to 19 existing holdings. Its largest new stake was Lam Research: 40,329 shares worth $6.9M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Inhibrx, an estimated $1.91M trimmed.

  • Birchview Capital's largest Q4 2025 buy was Lam Research: 40,329 shares worth $6.9M.
  • Birchview Capital added most to Intellia Therapeutics in Q4 2025, an estimated $3.52M increase.
  • Birchview Capital's biggest Q4 2025 reduction was Inhibrx, cutting an estimated $1.91M.
  • Birchview Capital fully exited Axogen in Q4 2025, selling an estimated $2.12M.
  • Birchview Capital's ten largest holdings make up 55% of its $171M portfolio in Q4 2025.
  • Birchview Capital opened 11 new positions and closed 12 in Q4 2025.
  • Birchview Capital's portfolio value rose 29% quarter-over-quarter to $171M.

Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.